Company intelligence / Profile preview

TSH Biopharm Corporation Limited

Ownership: Private
Employees: ~76
Development stage: Commercial

Overview

The company has successfully completed bridging studies meeting primary endpoints for RNTA06 in chronic angina. It has multiple NDAs submitted and approved products like TuNEX. It also holds commercialization rights to liquid biopsy diagnostic products via partnership with CellMax Life in Taiwan[1][3].

Therapeutic areas: GastroenterologyImmunologyCardiovascular
Modalities: Small molecules (cardiovascular drugs, gastroenterology drugs, CNS drugs)Precision medical testing products including liquid biopsy diagnostics
Industry: Biotech

Drug pipeline

2 assets

DMTA07

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

InnoPharmax reauthorizationCellMax Cayman investmentCellMax Life

Beyond the preview

Go deeper on TSH Biopharm Corporation Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSH Biopharm Corporation Limited.

Explore the full profile